LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC 50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes In Vitro LRRK2-IN-7 (compound 25) is both a mouse breast cancer resistance protein (BCRP) substrate (mouse/human BCRP) and a potent human BCRP inhibitor (BCRP IC 50 = 0.12 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo In a 7 day rat dose limiting toxicity study, LRRK2-IN-7 (compound 25) is tolerated with no significant histopathology findings up to 100 mg/kg once a day (AUC tot = 330 μM·h) . In an acute (2 h) rat PK/PD study, LRRK2-IN-7 (compound 25) demonstrates a dose-dependent decrease in LRRK2 pS935 in rat brain striatum with an EC 50 = 0.18 nM . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.9 nM (LRRK2 Kinase)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
LRRK2-IN-7
CAS number：2307277-93-4 molecular formula：C24H26N6O
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2307277-93-4 | molecular formula | C24H26N6O |
| molecular weight | 414.50 g/mol | Exact mass | ≥98% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
